In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Some of the best stocks to buy could be those falling the most. Zaven Boyrazian explores the worst-performing US shares for ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

The Harbor Long Term Growers ETF returned 5.97% underperforming the benchmark, the Russell 1000 Growth Index, which returned ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

The Harbor International Fund returned -8.22%, slightly underperforming its benchmark, the MSCI EAFE (ND) Index, which ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

And last December, shareholders were reminded of this when the results of its brand-new weight-loss drug, CagriSema, fell short of expectations. While the drug appears to be effective, average ...